DDInter154 DDInter741
Azelastine is a phthalazine compound having an oxo substituent at the 1-position, a 1-methylazepan-4-yl group at the 2-position and a 4-chlorobenzyl substituent at the 4-position. It has a role as a H1-receptor antagonist, an anti-allergic agent, an anti-asthmatic drug, a bronchodilator agent, a platelet aggregation inhibitor and an EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor. It is a member of phthalazines, a tertiary amino compound and a member of monochlorobenzenes.
Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder drug by Sprout Pharmaceuticals. Flibanserin's mechanism of action is attributed to its high affinity for 5-HTA1 and 5-HTA2 receptors, displaying agonist activity on 5-HTA1 and antagonist on 5-HTA2, resulting in lowering of serotonin in the brain as well as an effect on increasing norepinephrine and dopamine neurotransmitters.
Azelastine {u} (Compound) resembles {v} (Compound) Clemastine
Clemastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Flibanserin
Azelastine {u} (Compound) binds {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) is bound by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Flibanserin
Azelastine {u} (Compound) resembles {v} (Compound) Clemastine
Clemastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phenindamine
Phenindamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Flibanserin
Azelastine {u} (Compound) binds {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) is bound by {v} (Compound) Lansoprazole
Lansoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Flibanserin
Azelastine {u} (Compound) resembles {v} (Compound) Clemastine
Clemastine {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Doxylamine
Doxylamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Flibanserin
Azelastine {u} (Compound) resembles {v} (Compound) Clemastine
Clemastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Opium
Opium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Flibanserin
Azelastine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ivacaftor
Ivacaftor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Flibanserin
Azelastine {u} (Compound) upregulates {v} (Gene) NOTCH1
NOTCH1 {u} (Gene) is upregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Flibanserin
Azelastine {u} (Compound) upregulates {v} (Gene) NOTCH1
NOTCH1 {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Flibanserin
Azelastine {u} (Compound) downregulates {v} (Gene) DERA
DERA {u} (Gene) is downregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Flibanserin
Azelastine (Compound) resembles Clemastine (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Azelastine (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Flibanserin
Azelastine (Compound) resembles Clemastine (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Azelastine (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Lansoprazole (Compound) and Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Azelastine (Compound) resembles Clemastine (Compound) and Clemastine (Compound) resembles Doxylamine (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Azelastine (Compound) resembles Clemastine (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Azelastine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound) and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Azelastine (Compound) upregulates NOTCH1 (Gene) and NOTCH1 (Gene) is upregulated by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Flibanserin
Azelastine (Compound) upregulates NOTCH1 (Gene) and NOTCH1 (Gene) is upregulated by Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Azelastine (Compound) downregulates DERA (Gene) and DERA (Gene) is downregulated by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Flibanserin